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Summary
The term “duty to recontact” refers to the possible eth-
ical and/or legal obligation of genetics service providers
(GSPs) to recontact former patients about advances in
research that might be relevant to them. Although cur-
rently this practice is not part of standard care, some
argue that such an obligation may be established in the
future. Little information is available, however, on the
implications of this requirement, from the point of view
of GSPs. To explore the opinions of genetics profes-
sionals on this issue, we sent a self-administered ques-
tionnaire to 1,000 randomly selected U.S. and Canadian
members of the American Society of Human Genetics.
We received 252 completed questionnaires. The major
categories of respondents were physician geneticist
(41%), Ph.D. geneticist (30%), and genetic counselor
(18%); 72% of the total stated that they see patients.
Respondents indicated that responsibility for staying in
contact should be shared between health professionals
and patients. Respondents were divided about whether
recontacting patients should be the standard of care:
46% answered yes, 43% answered no, and 11% did not
know. Those answering yes included 44% of physician
geneticists, 53% of Ph.D. geneticists, and 31% of genetic
counselors; answers were statistically independent of
position or country of practice but were dependent on
whether the respondent sees patients (43% answered
yes) or not (54% answered yes). There also was a lack
of consensus about the possible benefits and burdens
of recontacting patients and about various alternative
methods of informing patients about research advances.
Analysis of qualitative data suggested that most respon-
dents consider recontacting patients an ethically de-
sirable, but not feasible, goal. Points to consider in
the future development of guidelines for practice are
presented.
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Introduction
Advances in medical genetics are occurring at an ex-
ponential rate. As a result of progress in the Human
Genome Project and in the elucidation of the genetic
bases of cancer and common multifactorial diseases, the
ability of genetics service providers (GSPs) to meet the
population’s needs for counseling and evaluation is be-
coming increasingly challenged. Added to the pressure
on GSPs of serving clients for so many new indications
is a growing awareness of another issue, the ethical and
possibly legal obligation to recontact former patients
when new developments occur.
From an ethical standpoint, among the situations in
which a moral obligation to recontact patients may be
considered to apply are (1) those in which a diagnosis
had been suspected, but not made, and a new diagnostic
test has been developed; (2) those in which a more ac-
curate diagnostic and/or prognostic test, postnatal or
prenatal, has been developed (e.g., from linkage to mu-
tation detection); and (3) those in which new informa-
tion may alter the prognosis or recurrence-risk estimates
(Fletcher et al. 1985; Andrews 1991; Coˆte´ et al. 1995).
Patients’ knowledge of advances in the molecular genetic
bases of their disorders may have great impact on their
lives, affecting their psychological well being, reproduc-
tive options, employment decisions, and lifestyle choices
such as marriage (Almqvist et al. 1997); in addition,
there is a consensus in the medical genetics community
that patients should have access to information about
such advances.
From a legal perspective, a physician’s “duty of care”
toward patients is considered to include the obligation
to advise them of any developments in management and
treatment that would be beneficial or detrimental
(Sharpe 1994) or that could cause them to choose an-
other course of action, no matter how remotely probable
(Pelias 1992). The duty of care was extended to include
the duty to patients formerly in care (the “duty to re-
call”), in the California case Tresemer v. Barke (86 Cal.
App. 3d 617 [1978]; 150 Cal. Rptr. 384 [1978]), in
which a physician who had inserted a Dalkon Shield (A.
H. Robins Co.) intrauterine contraceptive device was
held liable for failing to warn the woman 3 years later
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of its newly discovered health risks (Berg and Hirsh
1980). To date, no legal obligation for recontacting for-
mer patients when new genetic information becomes
available has been established, but some have argued
that such an obligation could find support in U.S. courts
(Andrews 1991; Pelias 1991).
Little information is available on the implications of
formalizing a duty to recontact with regard to the pro-
vision of genetics services. Establishing such liability
could mean that any one visit to a geneticist could result
in a perpetual duty of care for the provider, leading to
burdensome requirements for the storage and retrieval
of information (Hannig et al. 1993) and to the diversion
of funds for case review and management (Coˆte´ et al.
1995) that may be better spent in other areas. Moreover,
as Andrews (1991) reminded us, for many physicians in
other specialties, recontacting patients when new infor-
mation is available to aid their condition is not typical
practice; such information is imparted during routine
follow-up care but does not extend to former patients.
One may argue that geneticists should be able to make
the same distinction between their responsibilities to pa-
tients currently being followed up and to those dis-
charged from care. Finally, one may argue that the ge-
neticist, in the role of the consultant, has neither the
right nor the obligation to recontact former patients di-
rectly and that the responsibility for keeping patients up
to date rests with primary care physicians.
Is keeping former patients informed about research
advances a desirable goal? If so, should responsibility
be placed solely on GSPs? Might other health care pro-
viders or societal groups, such as the media, genetic sup-
port groups, and/or patients themselves, share some of
this responsibility? As a first step in the exploration of
this complex issue, we undertook to document the at-
titudes of GSPs toward (1) the locus of responsibility in
keeping patients informed of new developments in mo-
lecular genetics and (2) the possible considerations, both
ethical and logistical, of addressing the duty to recontact
in the future.
Subjects and Methods
In a previous study (Huggins et al. 1996), 43 adult
patients and the parents of patients with a diagnosis of
neurofibromatosis (NF) type 1, who were followed at
the Hospital for Sick Children in Toronto, completed a
questionnaire that assessed their attitudes toward the
duty of various health professionals to recontact them
in the event of improvements in the ability to diagnose
NF or to conduct prenatal testing, predict the clinical
course, or provide treatment for this condition. Addi-
tional questions solicited opinions about the responsi-
bility of both patients and health care providers to stay
informed about research advances.
To survey the attitudes of GSPs toward the duty to
recontact, we developed a questionnaire asking many of
the same questions and added another series of questions
about the duty to recontact in general. The current study
questionnaire consisted of the following four parts:
1. “Personal Background”: five questions designed to
assess the professional’s demographic characteristics and
amount and type of clinical activity performed.
2. “The Duty to Recontact: Advances in Neurofibro-
matosis Type I Research”: eight questions posed previ-
ously to NF patients and family members, the responses
to which were compared to those of the patient popu-
lation studied previously.
3. “The Duty to Recontact: Current Practice”: two
questions designed to assess whether respondents are
already recontacting patients in their practice.
4. “The Duty to Recontact: Theoretical Considera-
tions”: five items eliciting opinions as to the locus of
responsibility in keeping patients informed about re-
search advances; that is, whether recontacting patients
should be formalized into a standard of care, the most
important considerations in determining whether or
when recontacting a patient would be appropriate, and
the merit of various possible informal methods of en-
suring that patients are kept informed about future ad-
vances in research.
The questions for sections 2–4, as they appeared on
the questionnaire, and details of how respondents were
instructed to answer them are presented in Results. Com-
ments were requested for many of the questionnaire
items. Such qualitative data were solicited to help in-
terpret and explain any statistically significant quanti-
tative observations and to enrich our understanding of
the opinions held by the GSP respondents.
A pilot study using the questionnaire was performed
with 20 volunteer genetics professionals and trainees
from the Hospital for Sick Children and the University
of Michigan. The questionnaire was revised subse-
quently on the basis of the feedback received. The revised
questionnaire, together with an explanatory cover letter
and a return envelope without postage, was mailed to
1,000 randomly selected members of the American So-
ciety of Human Genetics (ASHG) who live in the United
States ( ) or Canada ( ). Participants in then  940 n  60
pilot study were excluded. Respondents had 4 wk to
return the questionnaire, and responses were anony-
mous. On receipt of the completed questionnaires, items
were coded, and the responses were entered into the
computer program Microsoft Excel 5.0, for statistical
analysis.
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Figure 1 Mean response to the question “Who is responsible
for ensuring that patients and their families stay informed about ad-
vances in research?” The question was asked of GSPs in this study
and NF family members in a previous study, and it applied to research
advances in four areas: diagnostic testing, prenatal diagnosis, predic-
tion of the progression of symptoms, and treatment for NF. A scale
of 1–5 was used, in which 1  patient responsibility and 5  health
care–provider responsibility. HCPs  health care providers.
Results
We received replies from 267 individuals. Of these,
10 indicated that they would not be participating, 1
returned a letter explaining his opinions, and 4 returned
their questionnaires after the deadline; these 15 were not
counted statistically. The remaining 252 completed ques-
tionnaires were counted, yielding a response rate of
25%.
Personal Background
Respondents from the United States numbered 234
(93%), and those from Canada numbered 18 (7%).
These response numbers corresponded closely to the
proportion of questionnaires mailed to the two countries
(94% and 6%, respectively). Of all the respondents,
72% stated that they see patients; 12% of all respon-
dents work in a research laboratory, 21% work in a
laboratory that performs both research and clinical serv-
ice, 17% work in a service-only or diagnostic laboratory,
and the remaining 49% do not work in a laboratory.
With respect to position, the major categories of re-
spondents were physician geneticist (41%), Ph.D. ge-
neticist (30%), and genetic counselor (18%). Ph.D. ge-
neticists included professionals involved in teaching,
research, and/or clinical activities. The remaining 11%
of respondents were assigned various other categories,
such as genetics nurse, graduate student, or laboratory
technologist. Our sample appears to be skewed, with a
higher proportion of respondents involved in clinical
activities, compared with the ASHG membership as a
whole. In 1997, of the 76% of ASHG members who
had submitted membership-profile surveys, 11% were
genetic counselors, 26% held M.D. degrees, and 32%
held Ph.D. degrees; we considered the latter two per-
centages to be loose approximations of the proportions
of physicians and Ph.D. geneticists (Smith 1997). In our
view, this skew in the distribution of respondent char-
acteristics is a reflection of the clinical relevance of the
topic under consideration.
The Duty to Recontact: Advances in
Neurofibromatosis Type I Research
“Who is responsible for ensuring that patients and
their families stay informed about advances in re-
search?”—Respondents were asked to select a number
from a scale of 1–5, in which 1 represented patient re-
sponsibility, 5 represented health care–provider respon-
sibility, and 2–4 represented some degree of shared re-
sponsibility for keeping patients informed. The question
was asked as it pertained to four types of research ad-
vances: diagnostic testing, prenatal diagnosis, prediction
of the progression of symptoms, and treatment of NF.
Overall, respondents indicated that responsibility for
keeping patients informed about research advances
should be shared, with health care providers having
slightly more responsibility than patients. On the “re-
sponsibility scale” of 1–5, the mean responses for the
four types of research advances were 3.2, 3.4, 3.4, and
3.6, respectively, as shown in figure 1. These values were
not significantly different from those based on the re-
sponse of the NF families studied previously (two-sam-
ple z-test, ). Because the NF families studied pre-P ! .05
viously were from Canada but most of our GSP
respondents were from the United States, we performed
a separate analysis of the subset of GSP respondents
from Canada ( ). Among this group, the meann  18
responses for the four types of research advances were
3.1, 3.3, 3.5, and 3.6, respectively. The sample size for
the Canadian respondents was not sufficiently large to
allow comparisons with the previously studied sample
of patients; however, the results appear to follow a sim-
ilar trend.
“To what extent would each of the following health
professionals have a duty to recontact patients if there
were an advance in research?”—In a second series of
questions, we asked subjects the extent to which various
types of health professionals have a duty to recontact.
The categories of health professional were family doctor,
clinical geneticist, genetic counselor, general pediatri-
cian, other consultant physician(s)—such as neurologist,
ophthalmologist, or surgeon—and other. Respondents
were asked to select a number from a scale of 0–5, in
which 0 represented no duty and 5 represented a great
degree of duty, for each type of health professional. Once
again, the question was asked as it pertained to four
types of research advances: diagnostic testing, prenatal
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Figure 2 Mean responses to the question “To what extent would each of the following health professionals have a duty to recontact
patients if there were an advance in research?” The question was asked of GSPs in this study and NF family members in a previous study, and
it applied to research advances in four areas: diagnostic testing (A), prenatal diagnosis (B), prediction of the progression of symptoms (C), and
treatment for NF (D). A scale of 0–5 was used, in which 0  no duty and 5  a great degree of duty. “Doc.”  doctor, “Clin. Genet.” 
clinical geneticist, GC  genetic counselor, “Gen. Ped.”  general pediatrician, and “other MD”  other consultant physician.
diagnosis, prediction of the progression of symptoms,
and treatment of NF.
The mean responses to these questions are depicted
in figure 2. For each type of research advance, GSP re-
spondents assigned the highest degree of duty to clinical
geneticists and the second highest degree of duty to either
genetic counselors or family doctors. Among the NF
family members studied previously, the highest degree
of duty was assigned to clinical geneticists, and the sec-
ond highest degree of duty was assigned to genetic coun-
selors, for each type of research advance. Comparison
of the results from the two samples revealed that, for
each category of health professional and for each type
of research advance, NF family members assigned a
higher mean degree of duty to the health professionals
than did the GSPs. For the category of family doctor
and hypothetical research advances in diagnostic testing
(fig. 2A), prediction of the progression of symptoms (fig.
2C), and treatment (fig. 2D), differences between sample
means were not statistically significant; for all other cat-
egories and each type of research advance, differences
were significant (two-sample z-test, ). We noteP ! .01
that, for research advances in prenatal diagnosis (fig.
2B), 46 respondents appropriately added obstetrician/
gynecologist in the “other” category, assigning a mean
degree of duty of 4.3. However, this could not be fac-
tored into the comparison of results for the other clinical
scenarios. When the results for the four types of research
advances were compared, the highest degree of duty was
assigned, by both groups, to hypothetical advances in
the treatment NF.
Again, the sample size of Canadian GSP respondents
( ) was too small to draw conclusions about hown  18
their opinions compared with those of the (Canadian)
NF family members studied previously. Subjectively,
however, they followed similar trends. Canadian GSP
respondents assigned the highest degree of duty to clin-
ical geneticists, in three of the four categories of research
advances; they assigned a lower mean degree of duty to
health professionals than did the NF family members,
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for each category of health professional and for each
type of research advance; and they assigned the highest
degree of duty overall for hypothetical advances in the
treatment of NF.
The Duty to Recontact: Current Practice
“Have you personally ever recontacted a patient re-
garding research advances?”—Sixty-one percent of re-
spondents answered yes, 32% answered no, and 7%
answered that they did not recall.
“Has your department/unit established a formal sys-
tem for the specific purpose of recontacting patients
about research developments?”—Thirteen percent of re-
spondents answered yes, 77% answered no, and 10%
answered that they did not know. Comments were re-
quested for this question, and 63 (25%) respondents
provided them. The majority of comments from those
answering yes specified existing systems for recontacting
patients. Responses revealed a wide variation in inter-
pretation of the word “formal”: “Yes, we ask patients
to contact us annually”; “yes, continually updated da-
tabase, by case, by condition, and quarterly question-
naires to patients in on-going therapy.” The majority of
comments from those answering no served to justify
their response: “We have 30,000 charts going back 25
years! We have neither the staff nor time to do this sys-
tematically!!” “Who will pay? Unless this service is part
of capitation or managed care it won’t happen.” One
respondent described actual experience with recontact-
ing patients: “No. Recontact was a waste of time. Very
little response to the letters and 50% of the patients had
moved. Patients must recontact at a defined interval.”
The Duty to Recontact: Theoretical Considerations
The hypothetical duty of GSPs was investigated sep-
arately from the hypothetical responsibility of patients
and without reference to a particular genetic disorder or
type of research advance.
“How much of an ethical or moral duty do genet-
ics service providers have to recontact former pa-
tients?”—On a scale of 1–5, in which 0 represented no
duty and 5 represented a great degree of duty, the mean
response was 3.4. The clinical GSPs felt that they have
some duty to keep patients informed about research ad-
vances. Space for comments was not provided for this
question, but a small number of respondents expressed
concerns such as the following: “Unless it becomes a
legal duty, the ethics and morality won’t carry much
weight in today’s medical climate.”
“How much responsibility do patients have to keep
in contact with genetics service providers?”—On a scale
of 1–5, in which 1 represented no responsibility and 5
represented a high degree of responsibility, the mean
response was 3.9. The degree of responsibility for main-
taining contact that the GSPs assigned to patients
was higher than the degree of duty they assigned to
themselves.
“Should recontacting patients about research ad-
vances be the standard of care for clinical genetics serv-
ice providers?”—Forty-three percent of respondents an-
swered yes, 46% answered no, and 11% indicated that
they did not know. Comments were requested for this
question also, and 86 respondents (34%) provided them.
One common theme among the comments from those
answering yes was philosophical support for recontact-
ing patients: “What other way is there to serve patients
appropriately”; “it’s part of the job description”; “re-
contact is a right and a responsibility for both patients/
families and physicians/laboratories.” However, most of
the comments from those answering yes served to qualify
their responses: “Funding needs to be pro-
vided for this responsibility by the government/public
‘friends’”; “but a follow up system which works auto-
matically and easily must be available for this to work
in any realistic fashion”; “one question will be when is
the research secure enough to recontact.” Thus, many
respondents who support the idea of recontacting pa-
tients would only do so under certain circumstances.
Comments from those answering no to this question are
typified by the following: “I believe in personal respon-
sibilities. To place this burden on health care providers
is unfair.” “You use legal terms ‘duty’ and ‘standard of
care.’ Translate: Do it or my trial lawyers groups will
sue.” “We completely lack resources. No other specialty
does it.” Those answering yes to the question included
44% of physician geneticists, 53% of Ph.D. geneticists,
and 31% of genetic counselors; answers were statisti-
cally independent of position or country of practice but
were dependent on whether the respondent sees patients.
Forty-three percent of the respondents who do see
patients felt that recontacting patients should be the
standard of care, whereas 54% of those who do not
see patients felt that it should (x2 independence test,
).P ! .05
Ethical, Legal, and Practical Considerations
Subjects were asked to consider various ethical, legal,
and practical considerations that might be significant if
a system for recontacting patients about research ad-
vances were to be established. They were asked to in-
dicate whether they felt that a particular issue would be
important in determining whether or when recontacting
a patient would be appropriate. Responses are shown
in table 1. Overall, more respondents identified as im-
portant the possible benefits to patients, compared with
the benefits to GSPs. The most frequently cited possible
burden for patients was anxiety and stress; for GSPs, it
was the staff time required. This question seemed to have
Fitzpatrick et al.: The Duty to Recontact 857
Table 1
Possible Considerations Involved If a Formal System for Recontacting Patients Were Established
Possible Burden
Percentage of
Respondents Possible Benefit
Percentage of
Respondents
Patients Anxiety and stress 82 Improved care (follow-up) 100
Intrusion of privacy 66 Reduced uncertainty 92
Concerns about health insurance 81 Renewed hope for the future 92
Concerns about life insurance 76
GSPs Staff time required 90 Better organization of workload 54
Cost of information storage and retrieval
(e.g., hardware/software)
79 Improved patient care (e.g.,
consistent follow-up)
94
Ensuring fairness for all patients 80 Reduced risk of litigation 63
Unlocatable patients 82
been unclear to many respondents, and, therefore, fur-
ther statistical analysis was not performed. However,
many respondents contributed their own items to the
lists of benefits and burdens, which we considered to be
informative. For example, “confusion” and “ambiguity”
were added as possible burdens for patients, and “pro-
viding some sense of control and participation in health
care” and “empowers patient” were added as possible
benefits. “Increased risk of litigation” and “defining how
much effort is sufficient” were added as possible burdens
for GSPs, and “seen as having something besides ‘talk’
to offer” and “fits into more familiar ‘medical’ model”
were added as possible benefits.
Other Methods of Ensuring That Patients
Stay Informed
As an alternative to a formal system for recontacting
patients, there may be informal, more feasible methods
of keeping families up to date about research develop-
ments. From a list of six such methods, subjects were
asked to choose two that they felt would be the most
effective. These methods and their relative appeal to re-
spondents are presented in table 2. No particular method
was seen as being far superior to any other. Responses
could be grouped into two broad categories—popular
options and less popular options. Popular methods in-
cluded suggesting that the patient call the GSP’s office
or that the family physician re-refer patients periodically
and informing relevant genetics support groups. Re-
spondents demonstrated little confidence in the media
and other types of health care providers, for the dis-
semination of information about advances in genetic
research.
Discussion
The concept of a possible ethical, moral, or legal duty
of clinical GSPs to recontact former patients about ad-
vances in research has received considerable attention in
recent years (Berg and Hirsh 1980; Andrews 1991; Pelias
1991, 1992; Sharpe 1994; Coˆte´ et al. 1995; Huggins et
al. 1996; Patenaude 1996; Almqvist et al. 1997). For
some time research and/or clinical service laboratories
have been grappling with the issue of so-called look-
back testing—that is, the retesting of previously obtained
samples with newly available probes, to identify muta-
tions (Hannig et al. 1993). Position papers on recon-
tacting patients are being prepared independently by the
Look-Back Subcommittee of the Social, Ethical, and Le-
gal Issues Committee of the American College of Med-
ical Genetics (K. Hirschhorn, personal communication)
and by the Ethics and Public Policy and Clinical Practice
Committees of the Canadian College of Medical Ge-
neticists (F. C. Fraser, personal communication). This
study, however, is the first to document the opinions on
this issue of a cross section of GSPs.
Overall, the opinions of the GSPs showed trends sim-
ilar to those of the NF family members studied previ-
ously. Both groups considered keeping patients informed
a shared responsibility, and both identified GSPs as hav-
ing the most duty to keep patients informed, among
various types of health professionals. In addition, both
groups were able to make some distinction in the duty
to recontact in different clinical situations, assigning the
highest degree of duty for hypothetical advances in the
treatment of NF. Our results suggest that, in the future,
patients and GSPs may enter into an effective partnership
in the pursuit of the shared goal of keeping patients
informed. As to the significantly greater degree of duty
assigned by the NF family members to the various health
professionals, compared with that assigned by the GSPs,
we note that interpretation of our results in this section
is limited by the fact that the sample of NF patients and
family members was drawn from a Canadian popula-
tion, whereas the vast majority of the current study sam-
ple was drawn from the United States. An interesting
topic to explore in future research might be whether such
differences in attitude are universal among patients ver-
sus GSPs or whether opinions on this issue vary with
sociological differences in consumerism and in the ec-
onomics of health care, between the two countries. Sub-
jective analysis of our results from the Canadian GSP
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Table 2
Most Effective Informal Methods of Ensuring That Patients Stay Informed about Research Advances
Method No. of Respondents
Asking patients to call GSP’s office at periodic intervals (e.g., once per year) 104
Asking patients to call GSP’s office if their clinical status or circumstances
change (e.g., if they become pregnant or if new symptoms develop)
92
Informing the media about specific research advances 45
Informing relevant genetics support groups about research advances 92
Informing other health care providers (e.g., community physicians) about
specific research advances or new technologies
43
Educating other health care providers (e.g., community physicians) about
the rapid pace of genetic research and the need to re-refer patients for
updated information
86
Other 16
NOTE.—Respondents were asked to choose two methods, and not every respondent answered this
question. Responses with more than two methods selected were not counted.
respondents, however, which revealed opinions similar
to those of the U.S. respondents, suggests that such dif-
ferences in attitude between patients and GSPs may be
universal. If it is true that patients assign a greater degree
of duty to health professionals than health professionals
assign to themselves, this might suggest a potential for
litigation: are patients with unmet expectations more
likely to sue than those whose expectations match those
of the providers of the delivery of care?
More than half of the respondents have recontacted
a past patient about a research advance, but only 13%
indicated that they have a formal system in place for
doing so. The many comments added in justification of
not having a formal system suggest that, although GSPs
may agree, in principle, that recontacting patients is in-
dicated under certain circumstances, they perceive sig-
nificant barriers to doing so systematically and view im-
plementation of a formal duty to recontact as requiring
a major investment of resources.
There was no consensus regarding whether recon-
tacting patients should be the standard of care for clin-
ical GSPs, with 46% of respondents answering yes, 43%
answering no, and 11% answering that they did not
know. However, analysis of demographic correlates to
a yes opinion demonstrated a trend, suggesting that
those with more clinical involvement are more likely to
feel that recontacting patients should not be the standard
of care.
Among respondents, there was also a lack of consen-
sus about the various possible benefits and burdens of
recontacting patients. One finding worthy of note, how-
ever, was that the GSPs perceived anxiety to be one of
the most important drawbacks, for patients, of being
recontacted. With regard to the patient’s point of view,
the desirability of being contacted systematically when
new information becomes available is unknown. Al-
though there is some evidence that patients feel that new
genetic-research findings need to be made more readily
available to them (Buxton and Pembrey 1996), there also
is evidence that recontacting patients may renew patient
anxiety (Almqvist et al. 1997). Further studies of patient
attitudes are warranted, to determine the extent to which
this perception is justified.
Our finding that the degree of responsibility for keep-
ing contact that the GSPs assigned to patients was
slightly higher than the degree of duty they assigned to
themselves suggests that, in addressing the possible duty
of keeping patients informed in the future, a policy of
putting more of the onus on the patient may be ac-
ceptable for GSPs. This is supported by our finding that
methods of keeping patients informed that put the onus
on the patient were popular, whereas methods involving
third parties, such as other health professionals or the
media, were less popular. Interestingly, despite the fact
that many respondents identified the family doctor as
having a relatively high degree of duty to keep patients
informed about advances, the option of informing other
health care providers about advances was among the
less popular alternative methods for doing so. Perhaps
by asking about the duty of various health professionals
to keep patients informed separately from the effective-
ness of various methods of doing so, we revealed an
inherent inconsistency in the opinions of the GSPs. If
GSPs consider family practitioners to be the most logical,
but not the most effective, facilitators of the transmission
of information about research developments, perhaps a
future task for GSPs would be to implement measures
to optimize this method of disseminating information.
We conclude that, although many GSPs support the
idea of recontacting patients about advances in research,
they perceive that such an endeavor would be impossible
within the confines of the current health care system.
On the other hand, the social, psychological, and ethical
implications of medical genetics may extend beyond
those of many other areas of medicine (Andrews 1991),
and patient expectations may dictate, in the future, pro-
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vider responsibility through litigation. GSPs may wish
to work proactively toward some method of addressing
this issue, either for ethical reasons or to protect them-
selves in court. The development of guidelines for clinical
practice that account for the expectations of patients
may serve this purpose.
Fletcher et al. (1985) proposed the establishment of
guidelines for clinical genetics when consensus exists,
emphasizing the need to consolidate what has been
learned about difficult moral choices. In their view, the
emergence of guidelines is a natural consequence of the
evolution of a field that has achieved specialty status in
medicine. Grimshaw and Russell (1993) conducted a
systematic review of the effect of clinical guidelines on
medical practice and found that 55 of 59 published eval-
uations that met defined criteria for scientific rigor
yielded significant improvements in the process of care
after their introduction. They concluded that explicit
guidelines do improve clinical practice, especially if the
development strategy is, among other factors, internal
to the specialty. Brook (1996) suggested that, for guide-
lines to be maximally effective, they must be based on
the best synthesis of scientific evidence and expert judge-
ment. On the basis of this published experience and the
results of this study, we propose an approach to the
establishment of practice guidelines for recontacting for-
mer patients, for GSPs.
We suggest that GSPs consider incorporating the fol-
lowing strategies into their practice. First, providers
might ask patients to accept more responsibility for
keeping informed about research advances. At the close
of a genetics consultation, GSPs might take a moment
to engage the patient in a brief discussion of the issue
of keeping patients up to date and the lack of resources
available to GSPs to do so. Simply mentioning this issue
may engender, among patients, some acceptance of re-
sponsibility in the form of a verbal agreement or at least
may educate them to the point that their expectations
of being recontacted are lowered. GSPs might ask that
patients contact them periodically (e.g., every 2 years)
or in the event of a change in clinical status or pregnancy,
for news of research developments. Consistent efforts
may be made to provide patients with Internet sites and
membership information for active support and/or re-
search societies and to encourage them to join such
groups so that they may receive newsletters and updated
information. Identification of patients who would prefer
not to be recontacted and documentation, in the chart,
of such informed refusal would be equally important.
Second, GSPs might increase their efforts to improve
the continuing education of and communication with
primary care providers so that they will be better
equipped to accept more responsibility in this area. Pri-
mary care providers in urban centers may have access
to in-services, conferences, and other continuing-edu-
cation opportunities and may know where to refer pa-
tients for genetics services, but this may not be true in
more-rural areas. Local and/or regional bulletins di-
rected to referring primary care providers, sent by either
regular or electronic mail, may be effective, particularly
if kept to one or two pages and presented in point form.
Standard paragraphs may be added in boldface type at
the end of clinic notes, to remind referring providers of
the rapid pace of genetics research and of the need to
re-refer patients for updated information if indicated.
Third, GSPs might establish working groups to delin-
eate priorities regarding the types of research develop-
ments, such as those that affect treatment or prevention,
that are most important to communicate to patients.
Patients may willingly accept more responsibility for
staying up to date if GSPs agree to recontact them when
a research advance would alter their prognosis. Finally,
we suggest that those professionals who would be most
affected by a policy for recontacting patients be inti-
mately—if not solely—involved in the process of devel-
oping guidelines for clinical practice.
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